Oramed Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oramed Pharmaceuticals Inc. on April 16, 2013. The report discloses the appointment of a new senior executive officer effective April 14, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Joshua Hexter as Chief Operating Officer (COO). Mr. Hexter joins the company from BioLineRx Ltd., where he served as a Director or Executive Director since 2007. Prior to BioLineRx, he was CEO of Biosensor Systems Design, Inc.
Compensation and Employment Terms
- Position: Chief Operating Officer.
- Effective Date: April 14, 2013.
- Employer: Oramed Ltd. (wholly-owned Israeli subsidiary).
- Salary: NIS 38,500 gross monthly.
- Equity Grant: Options to purchase 100,800 shares of common stock.
- Exercise Price: Market price on the Effective Date, with a floor of $6.00 per share.
Outlook and Risks
The filing contains no management commentary regarding future guidance, risks, contingencies, or unusual items. The document serves solely to disclose the executive appointment and associated employment agreement.
Key Facts for Investor Verification
- Verify the vesting schedule and expiration terms of the 100,800 stock options granted to the new COO, as these details are in the attached Exhibit 10.1.
- Confirm the current market price of Oramed common stock to determine the final exercise price of the options (subject to the $6.00 floor).
- Review the full Employment Agreement (Exhibit 10.1) for termination clauses and additional compensation not summarized in the 8-K.